Last reviewed · How we verify

idarubicin, etoposide, cytarbine, teniposide

St. Jude Children's Research Hospital · Phase 3 active Small molecule

idarubicin, etoposide, cytarbine, teniposide is a Combination chemotherapy regimen (topoisomerase II inhibitors and nucleoside analog) Small molecule drug developed by St. Jude Children's Research Hospital. It is currently in Phase 3 development for Acute leukemia in pediatric patients (St. Jude protocol-based treatment).

This is a combination chemotherapy regimen that uses multiple agents to damage cancer cell DNA and inhibit topoisomerase II, leading to cell death.

This is a combination chemotherapy regimen that uses multiple agents to damage cancer cell DNA and inhibit topoisomerase II, leading to cell death. Used for Acute leukemia in pediatric patients (St. Jude protocol-based treatment).

At a glance

Generic nameidarubicin, etoposide, cytarbine, teniposide
SponsorSt. Jude Children's Research Hospital
Drug classCombination chemotherapy regimen (topoisomerase II inhibitors and nucleoside analog)
TargetTopoisomerase II; DNA synthesis
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Idarubicin and etoposide are topoisomerase II inhibitors that prevent DNA unwinding and repair, while cytarabine is a nucleoside analog that incorporates into DNA and disrupts synthesis. Teniposide is also a topoisomerase II inhibitor. Together, these agents work synergistically to induce apoptosis in rapidly dividing leukemic cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about idarubicin, etoposide, cytarbine, teniposide

What is idarubicin, etoposide, cytarbine, teniposide?

idarubicin, etoposide, cytarbine, teniposide is a Combination chemotherapy regimen (topoisomerase II inhibitors and nucleoside analog) drug developed by St. Jude Children's Research Hospital, indicated for Acute leukemia in pediatric patients (St. Jude protocol-based treatment).

How does idarubicin, etoposide, cytarbine, teniposide work?

This is a combination chemotherapy regimen that uses multiple agents to damage cancer cell DNA and inhibit topoisomerase II, leading to cell death.

What is idarubicin, etoposide, cytarbine, teniposide used for?

idarubicin, etoposide, cytarbine, teniposide is indicated for Acute leukemia in pediatric patients (St. Jude protocol-based treatment).

Who makes idarubicin, etoposide, cytarbine, teniposide?

idarubicin, etoposide, cytarbine, teniposide is developed by St. Jude Children's Research Hospital (see full St. Jude Children's Research Hospital pipeline at /company/st-jude-children-s-research-hospital).

What drug class is idarubicin, etoposide, cytarbine, teniposide in?

idarubicin, etoposide, cytarbine, teniposide belongs to the Combination chemotherapy regimen (topoisomerase II inhibitors and nucleoside analog) class. See all Combination chemotherapy regimen (topoisomerase II inhibitors and nucleoside analog) drugs at /class/combination-chemotherapy-regimen-topoisomerase-ii-inhibitors-and-nucleoside-analog.

What development phase is idarubicin, etoposide, cytarbine, teniposide in?

idarubicin, etoposide, cytarbine, teniposide is in Phase 3.

What are the side effects of idarubicin, etoposide, cytarbine, teniposide?

Common side effects of idarubicin, etoposide, cytarbine, teniposide include Myelosuppression, Nausea and vomiting, Mucositis, Alopecia, Cardiotoxicity, Infection.

What does idarubicin, etoposide, cytarbine, teniposide target?

idarubicin, etoposide, cytarbine, teniposide targets Topoisomerase II; DNA synthesis and is a Combination chemotherapy regimen (topoisomerase II inhibitors and nucleoside analog).

Related